{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:06:47Z","timestamp":1767035207862,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Chronic inflammation is a risk factor for head and neck squamous cell carcinoma (HNSCC) and other diseases. Prostanoid receptors are clearly involved in the development of many types of cancer. However, their role is not simple and is poorly understood in HNSCC.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Methylation profiles of prostanoid receptor family genes were generated for tumour samples obtained from 274 patients with HNSCC, including 69 hypopharynx, 51 larynx, 79 oral cavity, and 75 oropharynx tumour samples, by quantitative methylation-specific PCR. Promoter methylation was then evaluated with respect to various clinical characteristics and patient survival.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The mean number of methylated genes per sample was 2.05\u2009\u00b1\u20092.59 (range 0 to 9). Promoters of <jats:italic>PTGDR1<\/jats:italic>, <jats:italic>PTGDR2<\/jats:italic>, <jats:italic>PTGER1<\/jats:italic>, <jats:italic>PTGER2<\/jats:italic>, <jats:italic>PTGER3<\/jats:italic>, <jats:italic>PTGER4<\/jats:italic>, <jats:italic>PTGFR<\/jats:italic>, <jats:italic>PTGIR<\/jats:italic>, and <jats:italic>TBXA2R<\/jats:italic> were methylated in 43.8%, 18.2%, 25.5%, 17.5%, 41.2%, 8.0%, 19.3%, 20.4%, and 11.3% of the samples, respectively. Methylation indices for prostanoid receptor family genes tended to be higher as the number of <jats:italic>TET<\/jats:italic> methylation events increased. Patients with 5\u20139 methylated genes had a significantly lower survival rate than that of patients with 0\u20134 methylated genes (log-rank test, P=\u20090.007). In multivariate analyses, <jats:italic>PTGDR1<\/jats:italic> methylation was most highly correlated with recurrence in patients with hypopharyngeal cancer (P\u2009=\u20090.014). A similar correlation was observed for <jats:italic>PTGER4<\/jats:italic> in patients with laryngeal cancer (P\u2009=\u20090.046). Methylation of the <jats:italic>PTGIR<\/jats:italic> and <jats:italic>TBXA2R<\/jats:italic> promoters was positively correlated with recurrence in oropharyngeal cancer (P\u2009=\u20090.028 and P\u2009=\u20090.006, respectively). Moreover, Patients with 5\u20139 methylated genes were extremely lower of 5hmC levels (P\u2009=\u20090.035) and was correlated with increasing expression of <jats:italic>DNMT3A<\/jats:italic> and <jats:italic>DNMT3B<\/jats:italic> (P\u2009&lt;\u20090.05 and P\u2009&lt;\u20090.05, respectively).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We characterised the relationship between the methylation status of prostanoid receptor genes and recurrence in HNSCC. These results provide new perspectives for the development of molecular targeted treatment approaches.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-020-02214-1","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:05:34Z","timestamp":1579737934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-5682","authenticated-orcid":false,"given":"Kiyoshi","family":"Misawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Mima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamada","family":"Satoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Mineta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"2214_CR1","doi-asserted-by":"publisher","first-page":"575242","DOI":"10.1155\/2012\/575242","volume":"2012","author":"M Tezal","year":"2012","unstructured":"Tezal M. Interaction between chronic inflammation and oral HPV infection in the etiology of head and neck cancers. Int J Otolaryngol. 2012;2012:575242.","journal-title":"Int J Otolaryngol"},{"key":"2214_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.virusres.2016.11.002","volume":"231","author":"JT Guidry","year":"2017","unstructured":"Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res. 2017;231:139\u201347.","journal-title":"Virus Res"},{"issue":"7751","key":"2214_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(72)90411-4","volume":"1","author":"PM Stell","year":"1972","unstructured":"Stell PM. Smoking and laryngeal cancer. Lancet. 1972;1(7751):617\u20138.","journal-title":"Lancet"},{"issue":"7","key":"2214_CR4","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1172\/JCI97953","volume":"128","author":"D Wang","year":"2018","unstructured":"Wang D, DuBois RN. Role of prostanoids in gastrointestinal cancer. J Clin Invest. 2018;128(7):2732\u201342.","journal-title":"J Clin Invest"},{"issue":"8","key":"2214_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/ijms17081320","volume":"17","author":"R Bar-Shavit","year":"2016","unstructured":"Bar-Shavit R, Maoz M, Kancharla A, Nag JK, Agranovich D, Grisaru-Granovsky S, Uziely B. G protein-coupled receptors in cancer. Int J Mol Sci. 2016;17(8):1320.","journal-title":"Int J Mol Sci."},{"issue":"44","key":"2214_CR6","doi-asserted-by":"publisher","first-page":"76318","DOI":"10.18632\/oncotarget.19356","volume":"8","author":"K Misawa","year":"2017","unstructured":"Misawa K, Imai A, Mochizuki D, Misawa Y, Endo S, Hosokawa S, Ishikawa R, Mima M, Shinmura K, Kanazawa T, et al. Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis. Oncotarget. 2017;8(44):76318\u201328.","journal-title":"Oncotarget"},{"issue":"3","key":"2214_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2017.07.009","volume":"170","author":"D Wacker","year":"2017","unstructured":"Wacker D, Stevens RC, Roth BL. How ligands illuminate GPCR molecular pharmacology. Cell. 2017;170(3):414\u201327.","journal-title":"Cell"},{"key":"2214_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-pharmtox-011613-135921","volume":"54","author":"BC Heng","year":"2014","unstructured":"Heng BC, Aubel D, Fussenegger M. G protein-coupled receptors revisited: therapeutic applications inspired by synthetic biology. Annu Rev Pharmacol Toxicol. 2014;54:227\u201349.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"7","key":"2214_CR9","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms19071886","volume":"19","author":"AKS Arakaki","year":"2018","unstructured":"Arakaki AKS, Pan WA, Trejo J. GPCRs in cancer: protease-activated receptors, endocytic adaptors and signaling. Int J Mol Sci. 2018;19(7):1886.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"2214_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/ijms19041019","volume":"19","author":"M Majumder","year":"2018","unstructured":"Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK. EP4 as a therapeutic target for aggressive human breast cancer. Int J Mol Sci. 2018;19(4):1019.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"2214_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1194\/jlr.M019695","volume":"53","author":"S Alcolea","year":"2012","unstructured":"Alcolea S, Anton R, Camacho M, Soler M, Alfranca A, Aviles-Jurado FX, Redondo JM, Quer M, Leon X, Vila L. Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2. J Lipid Res. 2012;53(4):630\u201342.","journal-title":"J Lipid Res"},{"key":"2214_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0090-6980(02)00054-0","volume":"68\u201369","author":"K Tsuboi","year":"2002","unstructured":"Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat. 2002;68\u201369:535\u201356.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"2214_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.alit.2014.08.002","volume":"64","author":"T Honda","year":"2015","unstructured":"Honda T, Kabashima K. Prostanoids in allergy. Allergol Int. 2015;64(1):11\u20136.","journal-title":"Allergol Int"},{"issue":"4","key":"2214_CR14","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","volume":"79","author":"S Narumiya","year":"1999","unstructured":"Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193\u2013226.","journal-title":"Physiol Rev"},{"key":"2214_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13148-018-0485-0","volume":"10","author":"K Misawa","year":"2018","unstructured":"Misawa K, Mima M, Imai A, Mochizuki D, Misawa Y, Endo S, Ishikawa R, Kanazawa T, Mineta H. The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis. Clin Epigenetics. 2018;10:52.","journal-title":"Clin Epigenetics"},{"issue":"12","key":"2214_CR16","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.3390\/ijms19123707","volume":"19","author":"D Mochizuki","year":"2018","unstructured":"Mochizuki D, Misawa Y, Kawasaki H, Imai A, Endo S, Mima M, Yamada S, Nakagawa T, Kanazawa T, Misawa K. Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation. Int J Mol Sci. 2018;19(12):3707.","journal-title":"Int J Mol Sci."},{"issue":"7","key":"2214_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1089\/dna.2018.4597","volume":"38","author":"A Imai","year":"2019","unstructured":"Imai A, Mochizuki D, Misawa Y, Nakagawa T, Endo S, Mima M, Yamada S, Kawasaki H, Kanazawa T, Misawa K. SALL2 is a novel prognostic methylation marker in patients with oral squamous carcinomas: associations with SALL1 and SALL3 methylation status. DNA Cell Biol. 2019;38(7):678\u201387.","journal-title":"DNA Cell Biol"},{"issue":"15","key":"2214_CR18","first-page":"4399","volume":"48","author":"GA Kune","year":"1988","unstructured":"Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399\u2013404.","journal-title":"Cancer Res"},{"key":"2214_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fonc.2013.00181","volume":"3","author":"E Gurpinar","year":"2013","unstructured":"Gurpinar E, Grizzle WE, Piazza GA. COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol. 2013;3:181.","journal-title":"Front Oncol"},{"key":"2214_CR20","first-page":"3418975","volume":"2019","author":"RSY Wong","year":"2019","unstructured":"Wong RSY. Role of nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention and cancer promotion. Adv Pharmacol Sci. 2019;2019:3418975.","journal-title":"Adv Pharmacol Sci"},{"issue":"10","key":"2214_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/cancers10100348","volume":"10","author":"WHS Nasry","year":"2018","unstructured":"Nasry WHS, Rodriguez-Lecompte JC, Martin CK. Role of COX-2\/PGE2 mediated inflammation in oral squamous cell carcinoma. Cancers. 2018;10(10):348.","journal-title":"Cancers."},{"issue":"2","key":"2214_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017;36(2):289\u2013303.","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"2214_CR23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","volume":"31","author":"E Ricciotti","year":"2011","unstructured":"Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986\u20131000.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2214_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12967-014-0265-3","volume":"12","author":"T Kumai","year":"2014","unstructured":"Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. Tumor-derived TGF-beta and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med. 2014;12:265.","journal-title":"J Transl Med"},{"issue":"8","key":"2214_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/carcin\/bgg083","volume":"24","author":"JH Jeng","year":"2003","unstructured":"Jeng JH, Wang YJ, Chiang BL, Lee PH, Chan CP, Ho YS, Wang TM, Lee JJ, Hahn LJ, Chang MC. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis. 2003;24(8):1301\u201315.","journal-title":"Carcinogenesis"},{"key":"2214_CR26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1186\/s12885-015-1687-x","volume":"15","author":"A Kalmar","year":"2015","unstructured":"Kalmar A, Peterfia B, Hollosi P, Galamb O, Spisak S, Wichmann B, Bodor A, Toth K, Patai AV, Valcz G, et al. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer. 2015;15:736.","journal-title":"BMC Cancer"},{"issue":"22","key":"2214_CR27","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1158\/1078-0432.CCR-17-1222","volume":"23","author":"A Ooki","year":"2017","unstructured":"Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, et al. A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA. Clin Cancer Res. 2017;23(22):7141\u201352.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2214_CR28","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.3802\/jgo.2018.29.e17","volume":"29","author":"CC Chang","year":"2018","unstructured":"Chang CC, Wang HC, Liao YP, Chen YC, Weng YC, Yu MH, Lai HC. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings. J Gynecol Oncol. 2018;29(1):e17.","journal-title":"J Gynecol Oncol"},{"key":"2214_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mce.2017.08.019","volume":"461","author":"K Itcho","year":"2018","unstructured":"Itcho K, Oki K, Kobuke K, Yoshii Y, Ohno H, Yoneda M, Hattori N. Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma. Mol Cell Endocrinol. 2018;461:100\u20134.","journal-title":"Mol Cell Endocrinol"},{"issue":"53","key":"2214_CR30","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1038\/sj.onc.1210550","volume":"26","author":"Y Sugino","year":"2007","unstructured":"Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, Sugimoto T, Imoto I, Inazawa J. Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene. 2007;26(53):7401\u201313.","journal-title":"Oncogene"},{"issue":"6","key":"2214_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/cncr.23694","volume":"113","author":"L Tian","year":"2008","unstructured":"Tian L, Suzuki M, Nakajima T, Kubo R, Sekine Y, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T, Yoshino I. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Cancer. 2008;113(6):1396\u2013403.","journal-title":"Cancer"},{"issue":"11","key":"2214_CR32","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4161\/epi.26346","volume":"8","author":"SA Farkas","year":"2013","unstructured":"Farkas SA, Milutin-Gasperov N, Grce M, Nilsson TK. Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer. Epigenetics. 2013;8(11):1213\u201325.","journal-title":"Epigenetics"},{"key":"2214_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13148-015-0110-4","volume":"7","author":"I Cebola","year":"2015","unstructured":"Cebola I, Custodio J, Munoz M, Diez-Villanueva A, Pare L, Prieto P, Ausso S, Coll-Mulet L, Bosca L, Moreno V, et al. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer. Clin Epigenetics. 2015;7:74.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2214_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtho.2016.08.123","volume":"12","author":"G Weiss","year":"2017","unstructured":"Weiss G, Schlegel A, Kottwitz D, Konig T, Tetzner R. Validation of the SHOX2\/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 2017;12(1):77\u201384.","journal-title":"J Thorac Oncol"},{"issue":"16","key":"2214_CR35","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/onc.2016.397","volume":"36","author":"JF Hiken","year":"2017","unstructured":"Hiken JF, McDonald JI, Decker KF, Sanchez C, Hoog J, VanderKraats ND, Jung KL, Akinhanmi M, Rois LE, Ellis MJ, et al. Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer. Oncogene. 2017;36(16):2319\u201327.","journal-title":"Oncogene"},{"issue":"3","key":"2214_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10555-016-9625-1","volume":"35","author":"S Ausoni","year":"2016","unstructured":"Ausoni S, Boscolo-Rizzo P, Singh B, Da Mosto MC, Spinato G, Tirelli G, Spinato R, Azzarello G. Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer Metastasis Rev. 2016;35(3):413\u201326.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"2214_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000477255","volume":"40","author":"JP Klussmann","year":"2017","unstructured":"Klussmann JP. Head and neck cancer\u2014new insights into a heterogeneous disease. Oncol Res Treat. 2017;40(6):318\u20139.","journal-title":"Oncol Res Treat"},{"key":"2214_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-019-0079-0","volume":"3","author":"H Takeshima","year":"2019","unstructured":"Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019;3:7.","journal-title":"NPJ Precis Oncol"},{"issue":"36","key":"2214_CR39","doi-asserted-by":"publisher","first-page":"24480","DOI":"10.18632\/oncotarget.25333","volume":"9","author":"K Misawa","year":"2018","unstructured":"Misawa K, Imai A, Mochizuki D, Mima M, Endo S, Misawa Y, Kanazawa T, Mineta H. Association of TET3 epigenetic inactivation with head and neck cancer. Oncotarget. 2018;9(36):24480\u201393.","journal-title":"Oncotarget"},{"issue":"8","key":"2214_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/1940-6207.CAPR-14-0306","volume":"8","author":"N Ichimura","year":"2015","unstructured":"Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka F, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, et al. Aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev Res. 2015;8(8):702\u201311.","journal-title":"Cancer Prev Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-020-02214-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02214-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:15:11Z","timestamp":1611101711000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02214-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2214"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02214-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research methodology employed in this study was approved by The Institutional Review Board of the Hamamatsu University School of Medicine. All study subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}